Overview

Neoadjuvant Immunotherapy With Durvalumab and Tremelimumab for Bladder Cancer Patients Ineligible for Cisplatin

Status:
Terminated
Trial end date:
2020-05-18
Target enrollment:
Participant gender:
Summary
The trial assess the safety and antitumor activity of the anti-PD-L1 antibody Durvalumab in combination with the anti-CTLA4 antibody Tremelimumab.
Phase:
Phase 2
Details
Lead Sponsor:
University Hospital Inselspital, Berne
Collaborator:
AstraZeneca
Treatments:
Antibodies, Monoclonal
Cisplatin
Durvalumab
Immunologic Factors
Tremelimumab